Lung Cancer
Volume 62, Issue 1 , Pages 126-138 , October 2008

Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: How CONSORTed are the data?

  • Karin Pat
    • ,
  • Christophe Dooms
    • ,
  • Johan Vansteenkiste

      Affiliations

    • Corresponding Author InformationCorresponding author at: Respiratory Oncology Unit (Pulmonology), University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. Tel.: +32 16 346802; fax: +32 16 346803.
    web address

Received 30 December 2007 ,Revised 20 February 2008 ,Accepted 24 February 2008.

References 

  1. Souquet P, Chauvin F, Boissel S, Cellerino L, Ganz P, Kaasa S, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet. 1993;342:19–21
  2. Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899–909.
  3. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol. 1993;11:1866–1872
  4. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194
  5. Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer. 1998;34:1036–1044
  6. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer. 1999;24:17–24
  7. Elderly Lung Cancer Vinorelbine Italian Study Group . Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 1999;91:66–72
  8. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer. 2000;83:447–453
  9. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 2000;92:1074–1080
  10. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000;27:145–157
  11. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer. Ann Oncol. 2001;12:1671–1675
  12. Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, et al. Assessment of quality of life in the supportive care setting of the Big Lung Trial in non-small cell lung cancer. J Clin Oncol. 2005;23:7417–7427
  13. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999;17:3522–3530
  14. Vansteenkiste JF, et al. Clinical benefit response in advanced non-small cell lung cancer. A multicenter prospective randomized phase III study of single agent gemcitabine versus cisplatin–vindesine. Ann Oncol. 2001;12:1221–1230
  15. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3025–3034
  16. Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer. 2004;43:83–91
  17. Lilenbaum RC, Chen CS, Chidiac T, Schwarzenberger PO, Thant M, Versola M, et al. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small cell lung cancer. Ann Oncol. 2005;16:97–101
  18. Ten Bokkel Huinink WW, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen PL, et al. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer. 1999;26:85–94
  19. Sandler AB, Nemunaitis J, Denham C, Von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2000;18:122–130
  20. Gatzemeier U, Von Pawel J, Gottfried M, Velde GP, Mattson K, DeMarinis F, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol. 2000;18:3390–3399
  21. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol. 2000;18:2529–2536
  22. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–372
  23. Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol. 2004;22:2602–2609
  24. Sederholm C, Hillerdal G, Lamberg K, Kolbeck K, Dufmats M, Westberg R, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005;23:8380–8388
  25. Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, Van Zandwijk N, et al. Randomized study of paclitaxel–cisplatin versus cisplatin–teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998;16:2133–2141
  26. Cardenal F, Lopez Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabine–cisplatin versus etoposide–cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 1999;17:12–18
  27. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18:623–631
  28. Danson S, Middleton MR, O’Byrne KJ, Clemons M, Ranson M, Hassan J, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer. 2003;98:542–553
  29. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere lung cancer study group. J Clin Oncol. 2004;22:254–261
  30. Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, et al. Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005;16:1069–1075
  31. Rudd RM, Gower NH, Spiro SG, Eisen TG, Harper PG, Littler JA, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol. 2005;23:142–153
  32. Moinpour CM, Lyons B, Grevstad PK, Lovato LC, Crowley J, Czaplicki K, et al. Quality of life in advanced non-small cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res. 2002;11:115–126
  33. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002;13:1539–1549
  34. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol. 2002;20:4285–4291
  35. Fossella F, Pereira JR, Von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016–3024
  36. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small cell lung cancer. J Clin Oncol. 2002;20:1335–1343
  37. Douillard JY, Gervais R, Dabouis G, Le Groumellec A, D’Arlhac M, Spaeth D, et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Ann Oncol. 2005;16:81–89
  38. Smit EF, Van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol. 2003;21:3909–3917
  39. Wachters FM, Van Putten JW, Kramer H, Erjavec Z, Eppinga P, Strijbos JH, et al. First-line gemcitabine with cisplatin or epirubicin in advanced non-small cell lung cancer: a phase III trial. Br J Cancer. 2003;89:1192–1199
  40. Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K, et al. Front-line paclitaxel–vinorelbine versus paclitaxel–carboplatin in patients with advanced non-small cell lung cancer: a randomized phase III trial. Ann Oncol. 2004;15:1048–1055
  41. Laack E, Dickgreber N, Muller T, Knuth A, Benk J, Lorenz C, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004;22:2348–2356
  42. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005;23:2937–2945
  43. Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morere JF, et al. Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol. 2005;16:602–610
  44. Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, et al. Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005;49:233–240
  45. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer. 2004;43:183–194
  46. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer. 2004;91:1996–2004
  47. Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer. 2004;91:482–488
  48. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, Von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  49. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, et al. Phase III study of second-line chemotherapy for advanced non-small cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol. 2005;23:8389–8395
  50. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17:3188–3194
  51. Vansteenkiste J, et al. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: analysis of a randomised study. Lung Cancer. 2003;40:191–199
  52. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  53. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  54. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer. 1993;29A:51S–58S
  55. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199–220
  56. Schipper H, Clinch J, Mc Murray A, Levitt M. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984;2:472–483
  57. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chron Dis. 1981;34:585–597
  58. De Haes JC, Van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990;62:1034–1038
  59. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol. 2007;18:775–781

☆ Note: Data presented in part at the European Respiratory Society Meeting, Munich, September 2006.

PII: S0169-5002(08)00106-2

doi: 10.1016/j.lungcan.2008.02.018

Lung Cancer
Volume 62, Issue 1 , Pages 126-138 , October 2008

Article Tools

* Image Usage & Resolution